Bioinformation · 2019 · 40 citations · 35 references
PharmacyMedicinal ChemistryPharmacologyDrug DesignDrug DiscoveryMolecular OncologyCancer ImmunotherapyImmune Checkpoint InhibitorsMolecular DockingProtein-ligand DockingTargeted Cancer TherapyVirtual ScreeningCytotoxicity AssaysInhibitor ScreeningInhibitor SelectivityMolecular Docking AnalysisPd-l1 BlockadeProgrammed Cell Death Protein 1 (Pd-1) PathwayProgrammed Cell Death Protein 1 InhibitorsProgrammed Death-1 Inhibition
The progression of lung cancer is associated with inactivation of programmed cell death protein 1, abbreviated as PD- 1 which regulates the suppression of the body's immune system by suppressing T- cell inflammatory activity and is responsible for preventing cancer cell growth. It is of interest to identify inhibitors for PD-L1 dimeric structure through molecular docking and virtual screening. The virtual screened compound XGIQBUNWFCCMAS-UHFFFAOYSA-N (PubChem CID: 127263272) displays a high affinity with the target protein. ADMET analysis and cytotoxicity studies further add weight to this compound as a potential inhibitor of PD-L1. The established compound BMS-202 still shows the high re-rank score, but the virtual screened drug possesses a better ADMET profile with a higher intestinal absorption value and lower toxicity.
35
Structural basis for small molecule targeting of the programmed death ligand 1 (PD-L1)
Krzysztof M. Żak, P. Grudnik, Katarzyna Guzik et al. · Oncotarget · 2016 · 423 citations · Full text
Katarzyna Guzik, Krzysztof M. Żak, P. Grudnik et al. · Journal of Medicinal Chemistry · 2017 · 360 citations · Full text
Kavisha Patidar, Aruna Deshmukh, Srinivas Bandaru et al. · Asian Pacific Journal of Cancer Prevention · 2016 · 44 citations · Full text